66. IgA nephropathy Clinical trials / Disease details
Clinical trials : 255 / Drugs : 255 - (DrugBank : 79) / Drug target genes : 35 - Drug target pathways : 137
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02433236 (ClinicalTrials.gov) | September 2015 | 29/4/2015 | Open Label Study of Fostamatinib in the Treatment of IgA Nephropathy | A Phase 2, Multi-Centre, Open Label Extension Study of Fostamatinib in the Treatment of IgA Nephropathy for Patients Who Participated in Study C-935788-050 | IGA Nephropathy | Drug: Fostamatinib Disodium tablet 100 mg;Drug: Fostamatinib Disodium tablet 150 mg | Rigel Pharmaceuticals | NULL | Withdrawn | 18 Years | 72 Years | Both | 0 | Phase 2 | NULL |